Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax

Leuk Lymphoma. 2023 Apr;64(4):897-899. doi: 10.1080/10428194.2023.2179361. Epub 2023 Feb 27.

Authors

Ahmed Aribi¹, Amandeep Salhotra¹, Brian Ball¹, Anthony Stein¹, Guido Marcucci¹, Vinod Pullarkat¹

Affiliation

¹ Department Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.

PMID: 36850055
DOI: 10.1080/10428194.2023.2179361

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Azacitidine* / therapeutic use
Bridged Bicyclo Compounds, Heterocyclic / adverse effects
Decitabine / therapeutic use
Humans
Leukemia, Myeloid, Acute* / diagnosis
Leukemia, Myeloid, Acute* / drug therapy
Remission Induction

Substances

Decitabine
venetoclax
Azacitidine
Bridged Bicyclo Compounds, Heterocyclic